The expanded use for Novo Nordisk's new basal insulin comes 15 months after the initial FDA approval.
Novo Nordisk has gained FDA approval for children and adolescents to use Tresiba (insulin degludec), the long-acting, once-a-day basal insulin that is the successor to Lantus.
Tresiba, approved by FDA in September 2015, is approved to improve glycemic control in patients with type 1 and type 2 diabetes from the age of 1 year through adulthood, making it the only insulin approved in both types of diabetes for patients that young.
A key advantage of Tresiba, its 25-hour half-life, would give young patients and their parents the flexibility of dosing just once a day.
“We are seeing a rise in the number of children and adolescents in the United States, especially those with type 2, and are proud to support these patients by offering new and effective treatment options,” said Todd Hobbs, MD, US chief medical officer for Novo Nordisk, in a statement. “It can be challenging for children with type 1 diabetes and their parents to manage blood sugar levels and keep up with multiple injections throughout an already busy day.”
FDA’s action was based on results of the BEGIN Young trial, a 26-week, phase 3b, randomized controlled trial which compared Tresiba’s results with those of Levemir (insulin determir, rDNA origin), a long-acting insulin analogue from Novo Nordisk approved in 2005. The results found that Tresiba improved glycemic control effectively in patients age 1 to 17 in combination with insulin aspart, a mealtime insulin.
Research Points to Potential MCIDs in Diabetes Distress Scale–17
November 29th 2023Researchers identified a value of at least 0.25 to be a minimal clinically important difference (MCID) in diabetes distress, and MCID values of 0.38 and 0.39 for emotional and interpersonal distress subscales and physician and regimen distress subscales, respectively.
Read More
How Can Employers Leverage the DPP to Improve Diabetes Rates?
February 15th 2022On this episode of Managed Care Cast, Jill Hutt, vice president of member services at the Greater Philadelphia Business Coalition on Health, explains the Coalition’s efforts to reduce diabetes rates through the Diabetes Prevention Program (DPP).
Listen
Balancing Care Access and Fragmentation for Better Outcomes in Veterans With Diabetes
April 22nd 2021The authors of a study in the April 2021 issue of The American Journal of Managed Care® discuss the possible reasons behind the link between care fragmentation and hospitalizations in veterans with diabetes, as well as potential opportunities to address disjointed care in the context of the widespread telehealth uptake seen during the COVID-19 pandemic.
Listen